GoldenGolden
Bain Capital Life Sciences

Bain Capital Life Sciences

Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally.

Founded in 1984, Bain Capital is an alternative investment firm. They manage $105 billion in assets across their eighteen global locations. Their Bain Capital Life Sciences is a venture capital fund which specializes in buyouts, inflection capital, growth capital, turnaround and private equity investments in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and life science technology sectors.

Bain Capital Life Science was initially raised in May 2017 at $720 million.

Investment

Bain Capital Life Sciences has invested in Annexon Biosciences, Aptinyx, Arcutis Biotherapeutics, Cerevel Therapeuticvs, Constellation Pharmaceuticals, Dicerna Pharmaceuticals Inc., Gynesonics, Hugel, InlfaRx, Kestra Medical Technologies, Marinus Pharmaceuticals, Rapid Micro Biosystems, Replimune, SpringWorks Therapeutics, Solid Biosciences and ViaCyte.

Bain Capital Life Sciences has exited their investments in SpringWorks Therapeutics, Dicerna Pharmaceuticals, Solid Biosciences, Aptinyx, Replimune Group, and InflaRx.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
May 18, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Interius BioTherapeutics, Inc.
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene...
BioSpace
May 17, 2021
BioSpace
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer.
FinSMEs
May 11, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.